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Abstract Background The impact of age and adjuvant
therapy on contralateral breast cancer (CBC) risk and
prognostic significance of CBC were evaluated. Patients
and Methods In 45,229 surgically treated stage I–IIIA
patients diagnosed in the Netherlands between 1989 and
2002 CBC risk was quantified using standardised incidence
ratios (SIRs), cumulative incidence and Cox regression
analysis, adjusted for competing risks. Results Median
follow-up was 5.8 years, in which 624 CBC occurred
<6 months after the index cancer (synchronous) and 1,477
thereafter (metachronous). Older age and lobular histology
were associated with increased synchronous CBC risk.
Standardised incidence ratio (SIR) of CBC was 2.5 (95%
confidence interval (95% CI) 2.4–2.7). The SIR of meta-
chronous CBC decreased with index cancer age, from 11.4
(95% CI 8.6–14.8) when <35 to 1.5 (95% CI 1.4–1.7) for
 60 years. The absolute excess risk of metachronous
CBC was 26.8/10,000 person-years. The cumulative inci-
dence increased with 0.4% per year, reaching 5.9% after
15 years. Adjuvant hormonal (Hazard rate ratio (HR) 0.58;
95% CI 0.48–0.69) and chemotherapy (HR 0.73; 95% CI
0.60–0.90) were associated with a markedly decreased
CBC risk. A metachronous CBC worsened survival (HR
1.44; 95% CI 1.33–1.56). Conclusion Young breast cancer
patients experience high synchronous and metachronous
CBC risk. Adjuvant hormonal or chemotherapy consider-
ably reduced the risk of CBC. CBC occurrence adversely
affects prognosis, emphasizing the necessity of long-term
surveillance directed at early CBC-detection.
Keywords Adjuvant systemic therapy 
Contralateral breast cancer  Prognosis  Radiotherapy
Introduction
Breast cancer is the most common malignancy in women in
North America and Western Europe. Contralateral breast
cancer (CBC) is the most frequent second cancer reported
after primary breast cancer, comprising between 30 and
50% of all second cancers [1–5]. Breast cancer patients
appear to have a two- to threefold increased risk of
developing CBC. Previous studies observed a constant
increase in CBC risk over time, up to a cumulative risk of
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5–7% 10 years after diagnosis [6–9]. However, most
studies included patients diagnosed and treated more than
15–20 years ago while indications for adjuvant treatment
have changed since.
Factors such as family history, young age and lobular
histology have been associated with increased CBC risk [6,
8, 10–12]. There is increasing evidence that adjuvant
treatment affects CBC risk. A meta-analysis by the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG)
showed that tamoxifen for 2 or 5 years resulted in pro-
portional reductions of the CBC incidence of 26% and
47%, respectively [13]. Recent data suggest that aromatase
inhibitors may be even more effective in reducing CBC
[14–16]. The EBCTCG meta-analyses showed also a
marginally significant 20% decrease in CBC risk after
adjuvant chemotherapy [17]. Radiation doses to the con-
tralateral breast are generally fairly low and rather unlikely
to confer an increased CBC risk. However, a large case-
control study did find an increased radiation-associated risk
among long-term breast cancer survivors diagnosed
between 1935 and 1982, who received radiotherapy before
age 45 [18]. A recent analysis of SEER data also found a
slightly increased CBC risk after radiotherapy in patients
aged <45 years, surviving longer than 5 years [6].
No recent data are available investigating the effects
of current breast cancer therapy on CBC risk among
unselected breast cancer patients. The effects of current
adjuvant treatment options on CBC occurrence and the
impact of CBC on patient survival are important and can
provide guidance for follow-up. Therefore we analysed
CBC occurrence in a large population-based cohort of
Dutch breast cancer patients, diagnosed between 1989
and 2002, evaluating the impact of age and treatment of
the index cancer and time since diagnosis on CBC risk.
In addition the prognostic significance of CBC was
studied.
Methods
Patients
The cohort comprises all surgically treated stage I–IIIA
(comprising TNM stages up to and including T3N1M0)
primary breast cancer patients diagnosed in the Compre-
hensive Cancer Centre North (CCCN), Amsterdam
(CCCA) and South (CCCS) regions from January 1989
until January 2003. Their cancer registries cover the
northwestern and southeastern part of the Netherlands, an
area with 7.2 million inhabitants (45% of the Dutch pop-
ulation). The cohort was composed in accordance to
privacy regulations of the Netherlands Cancer Registry
(NCR).
Data collection
PALGA, the nationwide Dutch network and registry of
histo- and cytopathology submits reports of diagnosed
malignancies to the Dutch cancer registries. The national
hospital databank, which receives discharge diagnoses of
all Dutch hospitals, completes case ascertainment. Registry
personnel collect data on diagnosis, stage and treatment
from the medical records using the registration and coding
manual of the NCR. All Dutch patients are treated in public
hospitals. Vital status and date of death were established
from the patient’s medical record or through linkage with
municipal population registries or the national death reg-
istry of the Central Bureau for Genealogy (CBG). Date of
censoring was set at 12-31-2004.
Stage was based on pathological information or clinical
information if pathology data were missing [19, 20]. All
primary cancers before or after the index breast cancer
were ascertained through a computerised record linkage
method. Patients with invasive breast cancer following a
non-invasive breast cancer, treated with ablation or
amputation, and patients with a previous invasive cancer
other than non-melanoma skin cancer were excluded. Any
CBC, not classified as a recurrence, was considered a pri-
mary CBC. Patients who presented with CBC and distant
metastases at diagnosis of this CBC were included. Infor-
mation on the occurrence of metastases during follow-up
was incomplete in the registries and determining whether
these metastases were due to the index cancer or due to the
CBC was not otherwise possible. To facilitate comparison
with international literature non-invasive CBC was exclu-
ded as event. Non-invasive CBC comprised about 10% of
all CBC and some 5% of the non-invasive CBC was fol-
lowed by an invasive CBC. Patients who developed a non-
invasive CBC, treated with ablation or amputation, were
censored at date of diagnosis of this tumour. An invasive
CBC diagnosed within 6 months of the index cancer was
defined as synchronous, all others as metachronous CBC.
Treatment
The prevailing treatment guidelines during the study period
are outlined below. Breast conserving surgery with axillary
lymph node dissection was indicated for tumours <4 cm,
complemented with radiotherapy to the breast. Alterna-
tively, a modified radical mastectomy was performed.
Loco-regional radiotherapy, consisting of parasternal,
axillary, infra and supra-clavicular nodal irradiation, was
indicated in case of >3 positive axillary nodes or extra-
nodal growth. Irradiation of the parasternal nodes was
indicated for node-positive patients with a medially located
tumour. Pre-menopausal node-positive patients received
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adjuvant chemotherapy, generally consisting of cyclophos-
phamide, methotrexate and 5-fluorouracil. Anthracycline-
based chemotherapy was increasingly used for high-risk
patients since the mid-1990s. Until 1998 post-menopausal
node-positive patients received 2 years tamoxifen. Since
1998, adjuvant systemic therapy was also administered to
node-negative patients with less favourable tumour char-
acteristics (intermediate or poorly differentiated tumours
 2 cm). Furthermore, since 1998 all hormone-receptor-
positive node-positive and unfavourable node-negative
patients were to receive 5-years tamoxifen, irrespective of
menopausal status. Inoperable and locally advanced cancers
received chemotherapy, hormonal therapy and/or
radiotherapy.
Statistical analysis
CBC risk was quantified using various risk measures. The
standardised incidence ratio (SIR) compares the observed
with expected numbers of CBC based on age- and calen-
dar-year specific breast cancer incidence rates for the
Dutch female population. The 1989, 1990, 1992, 1994,
1996, 1998, 2000 and 2002 incidence rates were derived
from the NCR and used to compute expected CBC num-
bers. Time at risk started at the date of index cancer
diagnosis for synchronous CBC and 6 months thereafter
for metachronous CBC and ended at the date of CBC
diagnosis, the date of death or the date of last linkage with
the municipal population registry or CBG. No information
on prophylactic contralateral mastectomies was available.
The CIs for the SIRs were calculated assuming a Poisson
distribution for the observed number of CBC. SIRs were
computed by age at diagnosis (<35, 35–39, 40–49, 50–59,
60–69, 70–79 and 80+), stage (T1N0, T2N0, T3N0, T1N1,
T2N1, T3N1), treatment (adjuvant chemotherapy, hor-
monal therapy or both combined (with or without
radiotherapy), adjuvant radiotherapy and surgery only)
and follow-up interval (<6 months, 6 months-4 years,
5–9 years and 10–14 years). Adjusted SIRs for metachro-
nous CBC by age, stage, treatment and follow-up period
were estimated with Poisson regression analysis. Poisson
model fit was evaluated using the Pearson Chi-square
goodness-of-fit test statistic. A high SIR does not neces-
sarily imply a high disease burden, as incidence rates for
specific age-groups may be low and the SIR is measured on
a multiplicative scale. The absolute excess risk (AER),
calculated by subtracting expected from observed CBCs
and dividing this figure by the accumulated number of
person-years (expressed per 10,000 person-years), better
estimates the excess disease burden.
Metachronous CBC cumulative incidence and confi-
dence intervals were estimated, with death or synchronous
CBC as competing risks [21, 22]. Cox Proportional Haz-
ards (CPH) analysis, accounting for competing risks, was
used to examine the effect of initial treatment on the risk of
developing a CBC [23]. A CPH model with a time-
dependent covariate, allocating follow-up time for each
patient to the ‘no CBC’ group until CBC occurrence, was
constructed to compare survival with and without CBC.
Variables considered in the model were age (continuous
variable), morphology, stage, and treatment at index cancer
diagnosis. Model fit was evaluated using residual-based
graphical methods and goodness-of-fit test statistics. All
reported P-values are two sided, the statistical significance
level was set at a P-value <0.05.
Results
The cohort comprised 45,229 women with breast cancer.
The median follow-up was 5.8 years (Inter Quartile
Range 3.4–9.1 years) and 12,584 patients died during
follow-up. The patients accumulated 295,097 person-
years, 83,396 person-years for the 5–9 year period and
21,379 person-years for the period  10 years after index
cancer diagnosis. Only 0.1% of the patients were followed
less than 6 months. In total 2,101 patients developed a
CBC, of which 624 were synchronous and 1,477
metachronous.
Risk of synchronous CBC
The frequency of synchronous CBC was 1.4% and
increased with age (P < 0.001, Table 1). A very high SIR
of synchronous CBC was observed for patients <35 years.
The SIR was markedly lower for patients aged 35–70 years
and increased again among those aged  70. A logistic
regression analysis showed an increase in risk of syn-
chronous CBC increased with older age (Odds ratio (OR)
for each 10-year increase 1.36; 95% CI 1.28–1.45),
presence of lymph node metastasis (OR 1.27; 95% CI
1.07–1.49) and for lobular index cancer histology (OR
1.56; 95% CI 1.28–1.91).
Relative risk of metachronous CBC
The SIR was 2.5 (95% CI 2.4–2.7) for all and 1.9 (95% CI
1.8–2.1) for metachronous CBC. In univariate Poisson
analysis the SIR of metachronous CBC decreased with age
at index cancer diagnosis; the SIR was 11.4 (95% CI 8.6–
14.8) for women <35 years and 1.5 (95% CI 1.4–1.7) for
women aged  60 years, respectively (P < 0.001,
Table 1).
Breast Cancer Res Treat (2008) 110:189–197 191
123
Table 1 Number of patients (No), observed number (O), frequency
(%) and standardised incidence ratios (SIR) of synchronous CBC and
observed number, 5- 10- and 15-year cumulative incidence (CR),
SIRs and absolute excess risk (AER) of metachronous CBC according
to age, stage and treatment of the index cancer
No Synchronous CBC Metachronous CBC
O % SIR 95% CI O SIR 95% CI AERa 5-year
CR (%)
10-year
CR (%)
15-year
CR (%)
All patients 45,229 624 1.4 10.4 9.6–11.3 1,477 1.9 1.8–2.1 26.8 2.1 4.2 5.9
Age
<35 1,198 13 1.1 81.7 43.5–139.8 58 11.4 8.6–14.8 72.8 2.9 6.1 7.4
35–39 1,999 7 0.4 9.7 3.8–20.9 85 4.9 3.9–6.1 53.8 2.9 4.6 7.0
40–49 9,121 78 0.9 9.7 7.6–12.1 343 2.4 2.1–2.7 34.4 2.4 4.5 6.9
50–59 11,179 129 1.2 8.6 7.1–10.2 346 1.8 1.5–2.0 22.5 1.9 4.3 6.1
60–69 10,386 140 1.4 8.5 7.1–10.0 334 1.5 1.3–1.8 18.3 1.8 4.2 6.1
70–79 8,056 159 2.0 11.6 9.8–13.6 255 1.7 1.5–2.0 25.3 2.1 4.0 5.3
80+ 3,290 98 3.0 17.2 13.9–20.9 56 1.2 0.9–1.6 7.8 1.4 2.0 2.3
Stage (TNM)
T1 N0 18,474 225 1.2 9.0 7.8–10.3 704 2.1 1.9–2.3 32.0 2.4 4.9 7.2
T2 N0 8,862 130 1.5 10.6 8.8–12.7 325 2.0 1.8–2.3 31.5 2.3 4.4 6.2
T3 N0 439 5 1.1 8.4 2.7–19.6 13 1.8 0.9–3.1 24.4 2.1 2.8 4.3
T1 N1 7,160 99 1.4 10.9 8.8–13.4 162 1.4 1.1–1.7 10.9 1.4 3.2 4.8
T2 N1 9,100 138 1.5 11.9 9.9–14.1 220 1.6 1.4–1.9 17.9 1.5 3.2 3.9
T3 N1 1,194 27 2.3 19.6 12.9–28.6 53 3.7 2.8–4.9 73.3 3.4 5.2 6.8
Adjuvant treatmentb
CT 6,121 59 1.0 10.7 8.1–13.9 177 2.3 1.9–2.7 29.1 2.0 3.9 5.4
HT 11,698 265 2.3 14.7 12.9–16.6 233 1.1 0.9–1.3 4.3 1.3 2.7 3.3
CT and HT 2,564 38 1.5 14.7 10.3–20.2 34 1.6 1.1–2.3 14.3 1.2 4.5 6.5
RT (without CT/HT) 13,044 91 0.7 5.3 4.2–6.6 527 2.2 2.0–2.4 34.4 2.4 4.9 7.5
No adjuvant treatment 11,802 171 1.5 10.3 8.8–12.0 506 2.2 2.0–2.5 37.5 2.6 5.0 6.8
a Absolute excess risk is expressed per 10,000 person years
b CT = chemotherapy, HT = hormonal therapy, RT = radiotherapy
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The SIR increased slightly with longer follow-up, from
1.8 after 0.5–4 years to 2.0 after 5–9 years and 2.1 after
10–14 years of follow-up (P = 0.081). However, as Fig. 1
shows the age-specific SIRs for metachronous CBC actu-
ally decreased with follow-up time for patients younger
than 40 years and increased only for older patients (inter-
action term age*follow-up period P < 0.001).
Crude SIRs of metachronous CBC were 1.1 (95% CI
0.9–1.3) following adjuvant hormonal therapy, 2.3 (95% CI
1.9–2.7) following adjuvant chemotherapy and 2.2 (95%
CI 2.0–2.4) for patients not receiving hormonal or che-
motherapy. Adjusted for age at index cancer diagnosis the
SIRs for both hormonal (SIR 0.9; 95% CI 0.6–1.2) and
chemotherapy (SIR 1.1; 95% CI 0.8–1.6) were in line with
expected CBC numbers based on Dutch female population
incidence rates, whereas the SIRs following surgery with/
without radiotherapy remained elevated (SIR 1.5; 95% CI
1.1–2.1).
Excess risk of metachronous CBC
The AER of developing a metachronous CBC was 26.8 per
10,000 woman-years (95% CI 23.2–30.4). The AER
decreased with age at index cancer diagnosis, from 72.7
(95% CI 51.3–94.2) to 7.8 (95% CI 7.7–23.4) per 10,000
person-years for women < 35 years and  80 years,
respectively. Adjuvant hormonal therapy was associated
with a very low AER of 4.3 (95% CI 2.3–11.0) per
10,000 person-years.
Cumulative incidence of metachronous CBC
The cumulative incidence for metachronous CBC was
2.1% (95% CI 1.9–2.3%) at 5 years, 4.2% (95% CI 3.9–
4.5%) at 10 years and 5.9% (95% CI 5.5–6.4%) at 15 years
of follow-up. The cumulative incidence increased at an
average rate of 0.4%/year. The highest cumulative inci-
dence was observed for patients younger than 40 years
(Fig. 2). The cumulative incidence increased with tumour
size when positive lymph node metastases were present
(Table 1). For patients receiving surgery only the 10-year
cumulative metachronous CBC incidence was 5.0% (95%
CI 4.5–5.5%).
Hormonal therapy (HR 0.57, P < 0.001) and chemo-
therapy (HR 0.79, P = 0.003) were associated with a lower
cumulative incidence of metachronous CBC compared to
patients not receiving adjuvant systemic therapy in uni-
variate CPH, adjusted for competing risks. Combined
adjuvant hormonal and chemotherapy was associated with
a decreased risk of CBC (HR 0.58, P = 0.002), similar in
magnitude to that for adjuvant hormonal therapy only.
In a multivariate CPH, treatment with adjuvant hormonal
(HR 0.58; 95% CI 0.48–0.69) or chemotherapy (HR 0.73;
95% CI 0.60–0.90), with or without radiotherapy, were
associated with a reduced CBC risk, compared to no adju-
vant systemic therapy (Table 2). The HR of a metachronous
CBC increased with tumour size, but decreased with age at
index cancer diagnosis. The histology of the index cancer
was not associated with metachronous CBC risk. The HR of
CBC did not differ between patients treated with surgery
and radiotherapy or surgery only. However, in a multivar-
iate CPH stratified for age, radiotherapy appeared
associated with a, albeit non-significantly, increased CBC
risk (HR 1.37 P = 0.111, Table 2A) after adjusting for
adjuvant hormonal and chemotherapy, age and stage. When
the analysis was restricted to 5-year survivors, hormonal
treatment was still associated with a decreased CBC risk
(HR 0.65; 95% CI 0.48–0.87, Table 2B).
Association of metachronous CBC with survival
Diagnosis of a CBC was associated with worse survival
compared to patients without CBC. The HR of death
Time after diagnosis (years)
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following CBC diagnosis was 1.44 (95% CI 1.33–1.56)
compared to patients without CBC. Table 3 shows that the
HR of death, adjusted for age and stage of the index cancer,
differed according to CBC stage. While a stage I CBC did
not increase the HR of death, stage II CBC increased the
risk of death 1.3 fold.
Discussion
In this large population-based cohort comprising over
45,000 breast cancer patients we observed a 2.5-fold
increased CBC risk. Assuming independence, the risk
expressed in breast-years would be twice as high as in breast
cancer survivors only one breast is at risk for CBC and the
reference incidence rates concern cancer in any of two
breasts. The cumulative incidence of metachronous CBC
increased by 0.4% annually and did not level off even after
10 years of follow-up. Furthermore, a metachronous CBC
in stage II or higher was associated with worse survival.
Very high SIRs of CBC were observed for the youngest
patients. Adjuvant hormonal and chemotherapy were
associated with a 42% and 27% risk reduction of meta-
chronous CBC, respectively. Adjusted for age, SIRs were
not elevated in patients receiving adjuvant systemic therapy.
In our study 1.4% of the patients were diagnosed with
synchronous CBC. Treatment does not likely affect the risk
of synchronous CBC, therefore this figure should be
directly comparable between studies. The frequency
reported in the literature varies between less than 1 and 3%,
largely depending on the time window chosen to define
synchronous CBC [9, 24, 25]. Our definition of synchro-
nous CBC, diagnosis within 6 months of the index cancer,
reflects the average time window in the literature. Differ-
ences in the diagnostic work-up, especially more frequent
use of bilateral mammography, can also affect the fre-
quency of synchronous CBC and may hamper comparison
between studies [26, 27]. Lobular histology was also found
associated with synchronous CBC occurrence, confirming
earlier findings [8–10].
Several studies have reported a decrease in the risk of
metachronous CBC with older age [6, 9, 11]. The very high
SIRs of both synchronous and metachronous CBC for the
youngest patients in our study were remarkable, with a
more than 11-fold increased risk of metachronous and a
more than 80-fold increased risk of synchronous CBC in
patients aged <35. This was accompanied by the highest
AERs, showing that these high SIRs cannot just be
explained by a lower background incidence. Early onset
breast cancer is a well recognized feature of hereditary
breast cancer and mutations of the BRCA1 or BRCA2
genes strongly predisposes for CBC development [28–30].
Magnetic resonance imaging (MRI) may have a place in
regular surveillance of these women [31]. Based on the
results of our study all young women with breast cancer
may be clear candidates for regular MRI screening directed
at early CBC detection.
The 10-year cumulative incidence of metachronous
CBC in our study (4.0%) was relatively low compared to
earlier studies [6–9]. This could be related to the increasing
application of adjuvant systemic therapy over the last
decades. In a study in patients diagnosed between 1975 and
1995 about 12.5% received hormonal therapy against about
32% in our study [9]. In our study hormonal therapy was
associated with a reduction of metachronous CBC risk by
42%. The reduction is comparable to the reduction seen in
the EBCTCG meta-analysis and might be even higher than
could be expected based on the EBCTCG meta-analysis,
especially considering the fact that most of our patients
received tamoxifen for 2 years only [13]. Our finding was
also in line with the reduction of invasive breast cancer
incidence observed in the NSABP tamoxifen prevention
trial [32]. Aromatase inhibitors may even further reduce
CBC risk [14–16]. Ongoing trials will determine the pre-
cise place of aromatase inhibitors, in terms of efficacy and
safety, for the adjuvant treatment of breast cancer. CBC
prevention will be an important endpoint in these studies.
Interestingly, we also observed that adjuvant chemotherapy
was associated with a 27% reduction of CBC. Although
less than after hormonal therapy, this risk reduction was
comparable to that seen in the polychemotherapy EBCTCG
meta-analysis [17].
In our study relatively few patients received combined
adjuvant systemic therapy and most were treated after
1997. Although our data do not allow firm conclusions
about the effect of combined adjuvant systemic therapy,
with a 42% proportional reduction of CBC occurrence
combined systemic therapy appeared to be associated with
a risk reduction similar to hormonal therapy alone.
Several studies have shown, that depending on the
radiation technique used, the contralateral breast receives
1–13% of the applied dose to the treated breast, with the
highest estimates reflecting scatter radiation to the medial
Table 3 Multivariate Cox regression analysis of overall survival,
with CBC as a time-dependent covariate
Risk factor HR 95% CI P-value
Stage of CBC (CBC yes versus no; time-dependent covariate)
Stage I 0.99 0.86–1.15 0.936
Stage II 1.32 1.13–1.54 <0.001
Stage III/IV 4.91 3.82–6.31 <0.001
Stage unknown 1.11 0.69–1.77 0.661
Adjusted for age and stage at index cancer diagnosis, both fitted as
time-varying covariates
HR = hazard ratio; 95% CI = 95% confidence interval
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part of the contralateral breast [33–35]. These doses are
well within the tumourigenic range. Studies in atomic
bomb survivors have shown decreasing radiation induced
breast cancer risks with advancing age and no increased
risk when irradiated over the age of 40 years [36].
Radiotherapy was not associated with a significantly
increased CBC risk in our study. However, adjuvant sys-
temic therapy is currently given to a high proportion of
patients aged <40 years (56% in our study) and a protective
effect of systemic therapy may well balance any increased
risk caused by irradiation. The SEER data revealed an
increased CBC risk associated with radiotherapy for
patients surviving  5 years, with a 1.3 fold risk increase
in patients aged <45 years at index cancer diagnosis [6].
When restricted to CBCs diagnosed  5 years after the
index cancer, radiotherapy before the age of 40 years was
not associated with CBC risk, although the risk estimate
(HR 1.4) was comparable with SEER data. Possibly longer
follow-up of our cohort may reveal an association between
radiotherapy and CBC risk.
Our study showed that metachronous CBC stage II or
higher was associated with worsened survival. Previously,
patients who developed CBC were found to be at increased
risk of disease recurrence and death [6, 8, 24]. An issue which
may affect all studies of CBC risk is the difficulty in distin-
guishing CBC from metastases of the index cancer. However,
several recent studies, which attempted to differentiate CBC
between metastasis and second primary cancer using molec-
ular-genetic techniques, did conclude that most localized
metachronous CBC were distinct entities [37–39]. Most
patients with metachronous CBC in our study were without
evidence of distant metastases. However, metachronous CBC
with distant metastases were not excluded and consequently
CBC risk may have been slightly overestimated.
The strengths of our study derive from its population-
based character. The cohort includes a large number of
patients with a nearly complete follow-up for vital status
and, based on cancer registry data, the follow-up for CBC
is virtually complete. Therefore this study provides a reli-
able estimate of the CBC risk and illustrates the potential
of adjuvant treatment for CBC prevention.
Our study does harbour some limitations. Information
on treatment for tumour recurrence was not recorded by the
cancer registries. Furthermore, some underestimation of
especially hormonal treatment may have occurred, as reg-
istration may sometimes have taken place before primary
treatment was completed, and may have resulted in some
underestimation of the effect of adjuvant treatment on CBC
risk. However, studies using cancer registry data for eval-
uation of breast cancer treatment guideline adherence in the
Netherlands showed generally good agreement between
registry treatment data and suggested treatment by guide-
lines [40–42]. Longer follow-up is required to determine
whether the prophylactic effect of tamoxifen on CBC
occurrence will persist over time. Also, the effect of more
prolonged tamoxifen (5 years instead of 2 years) and the
effects of combined chemo- and hormonal therapy on CBC
risk need further investigation.
As there is no evidence of a decreasing risk over time
and metachronous CBC negatively affects patient’s sur-
vival, regular long-term screening of the contralateral
breast remains necessary. A combined approach with MRI
and mammography appears most advisable for the youn-
gest patient group. With broadening indications for
adjuvant systemic treatment and new hormonal agents the
CBC incidence may further decrease in the future.
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